SAN DIEGO, California, December 20 /PRNewswire/ --

- First Molecular Test to Simultaneously Identify Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus from Nasal and Wound Specimens

GENEVA, Switzerland, December 20 /PRNewswire/ --

- Flamel's Medusa(R) Technology Designed to Allow Less Frequent Administration of Therapeutic Proteins and Peptides

SUNNYVALE, California, December 20 /PRNewswire/ --

- Music-Centric Social Networking Community Expands Language Offerings in Polish, German, Portuguese and Korean

Melodis Corp., a leader in search and sound recognition technologies, today announced the availability of Midomi.com in German, Korean, Portuguese and Polish. This latest advancement allows people to find, share, and record versions of music in these languages just in time for the holidays.

SAN MATEO, California, December 20 /PRNewswire/ --

NetSuite Inc. (NYSE: N) announced today the initial public offering of 6,200,000 shares of its common stock at a price of US$26.00 per share. NetSuite and certain selling stockholders have also granted the underwriters a 30-day option to purchase up to an additional 930,000 shares to cover over-allotments. NetSuite's common stock will begin trading on the New York Stock Exchange under the symbol "N" on Thursday, December 20, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20021024/SFTH024LOGO)

Credit Suisse Securities (USA) LLC acted as sole book-running manager for the offering and W.R. Hambrecht + Co., LLC acted as co-manager.

MINNEAPOLIS, December 19 /PRNewswire/ --

Nonin Medical, Inc., a leading innovator of physiological monitoring solutions, received the 2007 Industry Best Practices Award for Product Differentiation Innovation from Frost & Sullivan. Frost & Sullivan recognizes outstanding industry achievements and the Awards are recognized worldwide by the media, the investment community and end-user markets. The global growth consulting company honored Nonin for its pioneering vision that has transformed the vital sign monitoring industry and brought powerful, portable and easy-to-use pulse oximetry technology to more people and applications worldwide.

JEFFERSON, North Carolina, December 19 /PRNewswire/ --

Next Safety, Inc., a leader in developing pulmonary drug delivery devices, today announced verification of a significant breakthrough in pulmonary science that provides high efficacy delivery of drugs to the lungs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070615/CLF038LOGO )

Advanced optical characterization techniques performed by a third party laboratory showed that 99.8% of the droplets delivered by Next Safety's pulmonary drug delivery devices were between one and three microns in diameter, and the droplets separated sufficiently in space and time to be absorbed into the alveoli of the lungs.